About Liquidia Corporation
https://www.liquidia.comLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States.
CEO
Roger A. Jeffs
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:8.57M
Value:$342.54M
CALIGAN PARTNERS LP
Shares:8.12M
Value:$324.67M
BLACKROCK, INC.
Shares:5.23M
Value:$209.1M
Summary
Showing Top 3 of 215
About Liquidia Corporation
https://www.liquidia.comLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $54.34M ▲ | $49.4M ▲ | $-3.53M ▲ | -6.5% ▲ | $-0.04 ▲ | $3.89M ▲ |
| Q2-2025 | $8.84M ▲ | $45.05M ▲ | $-41.58M ▼ | -470.51% ▲ | $-0.49 ▼ | $-35.64M ▼ |
| Q1-2025 | $3.12M ▲ | $37.03M ▼ | $-38.37M ▲ | -1.23K% ▲ | $-0.45 | $-33.25M ▲ |
| Q4-2024 | $2.92M ▼ | $37.67M ▲ | $-38.37M ▼ | -1.32K% ▼ | $-0.45 ▼ | $-33.48M ▼ |
| Q3-2024 | $4.45M | $32.07M | $-23.16M | -520.57% | $-0.3 | $-19.55M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $157.5M ▼ | $275.98M ▲ | $253.93M ▲ | $22.05M ▲ |
| Q2-2025 | $173.42M ▲ | $257.41M ▲ | $242.22M ▲ | $15.19M ▼ |
| Q1-2025 | $169.76M ▼ | $227.43M ▼ | $177.72M ▲ | $49.71M ▼ |
| Q4-2024 | $176.48M ▼ | $230.31M ▼ | $153.04M ▲ | $77.28M ▼ |
| Q3-2024 | $204.37M | $252.89M | $142.37M | $110.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.53M ▲ | $-9.77M ▲ | $-911K ▲ | $-5.25M ▼ | $-15.93M ▼ | $-10.68M ▲ |
| Q2-2025 | $-41.58M ▼ | $-39.48M ▼ | $-1.06M ▼ | $47.71M ▲ | $7.17M ▲ | $-40.54M ▼ |
| Q1-2025 | $-38.37M ▲ | $-30.68M ▼ | $-330K ▲ | $24.29M ▲ | $-6.72M ▲ | $-31.01M ▼ |
| Q4-2024 | $-38.37M ▼ | $-20.81M ▲ | $-4.78M ▼ | $-2.3M ▼ | $-27.89M ▼ | $-25.6M ▲ |
| Q3-2024 | $-23.16M | $-25.08M | $-1.75M | $98.1M | $71.28M | $-26.83M |
Revenue by Products
| Product | Q4-2018 | Q2-2019 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $10.00M ▲ | $50.00M ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Collaboration And Licensing Milestones | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Collaboration And Licensing Non Refundable Upfront Payments | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 Research And Development Services | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Roger A. Jeffs
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
FARALLON CAPITAL MANAGEMENT LLC
Shares:8.57M
Value:$342.54M
CALIGAN PARTNERS LP
Shares:8.12M
Value:$324.67M
BLACKROCK, INC.
Shares:5.23M
Value:$209.1M
Summary
Showing Top 3 of 215